Drug Index


Mechanism :

The exact mechanism of action is unknown but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

Indication :

  • Treatment of moderate to severe pain

Contraindications :

Hypersensitivity, Abrupt withdrawal.

Caution in hepatic, renal or pulmonary disease.

Dosing :

>1 year to 18 years: 0.1 to 0.2 mg/kg IM/IV/subcutaneous every 3 to 4 hours. Maximum single dose: 20 mg; Maximum daily dose: 160 mg.

Adverse Effect :

Common Reactions: sedation, clamminess, dizziness, headache, dysphoria, nausea, vomiting, xerostomia, diaphoresis, urticaria, pruritus.

Serious Reactions: respiratory depression, bradycardia, hypotension, anaphylaxis/anaphylactoid reaction, hypersensitivity reaction, shock, laryngeal edema, dependency, abuse, withdrawal seizures if abruptly discontinued after prolonged use.

Interaction :

Alvimopan: Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
Cimetidine: Increases the effect of the narcotic.
Triprolidine: The CNS depressants, Triprolidine and Nalbuphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.

Hepatic Dose :

A reduced dose is recommended. Use with caution.
11/01/2020 13:23:55 Nalbuphine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0